![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 29, 26673-26680, July 19, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
andFrom the Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455
Received for publication, December 17, 2001, and in revised form, April 8, 2002
| |
ABSTRACT |
|---|
|
|
|---|
A yeast two-hybrid screen identified the
regulatory subunit of the calcium-dependent protease
calpain as a putative DNA ligase III-binding protein. Calpain binds to
the N-terminal region of DNA ligase III, which contains an acidic
proline, aspartate, serine, and threonine (PEST) domain frequently
present in proteins cleaved by calpain. Recombinant DNA ligase III was
a substrate for calpain degradation in vitro. This
calpain-mediated proteolysis was calcium-dependent and was
blocked by the specific calpain inhibitor calpeptin. Western blot
analysis revealed that DNA ligase III was degraded in human fibrosarcoma HT1080 cells following exposure to During programmed cell death, or apoptosis, cells are destroyed
via a highly orchestrated series of intracellular events. While this
process was discovered during studies of development, apoptosis also
plays a critical role in a number of processes that occur in the adult
organism, including tissue homeostasis and elimination of
virus-infected and tumor cells (1-5). A variety of signals can trigger
programmed cell death including tumor necrosis factor- The most studied of these proteases belong to the caspase gene family
and are encoded by homologs of the Caenorhabditis elegans ced 3 gene (1, 12). However mammalian apoptosis also
involves the activation of proteases encoded by the cathepsin (13) and calpain gene families (14-16). Activation of members of the caspase and cathepsin gene families occurs via proteolytic cleavage of inactive
zymogen forms (11, 17). In contrast, activation of calpains requires
elevated levels of cellular calcium (Ca2+), although these
proteins are further activated, and have their Ca2+
requirement reduced by autolysis that occurs following the initial Ca2+-dependent activation (18-21).
Proteases involved in apoptosis appear to hydrolyze target proteins at
a limited number of specific recognition sites. For example, most
members of the caspase family cleave proteins at the C-terminal end of
a 4-amino acid sequence containing a terminal aspartic acid residue
(11, 22), whereas calpains specifically cleave proteins containing
regions rich in proline, aspartate, serine, and threonine residues
called PEST1 motifs (23, 24).
Proteolytic cleavage can activate the target protein, as in the case of
autolysis of calpains, caspase-activated deoxyribonuclease, or MEKK-1
kinase (25, 26). However, in many cases proteolysis leads to
inactivation of the protein (27, 28). The range of cellular proteins
that undergoes specific degradation during apoptosis is extensive and
includes cell cycle regulatory proteins (i.e. p21 (29)),
cytoskeletal elements (i.e. actin, fodrin, and lamin
(30-32)), and signal transduction proteins (i.e. protein
kinase C, Akt1 (33-35)).
During apoptosis triggered by DNA damage, caspase 3 hydrolyzes a number
of proteins involved in DNA damage recognition and repair. For example,
the catalytic subunit of the DNA-dependent protein kinase
is cleaved by caspase 3 following exposure to ionizing radiation (IR)
(36). In addition, it has been shown that poly(ADP-ribose) polymerase
(37) and the ataxia telangiectasia-mutated protein (38) are cleaved by
this enzyme in cells exposed to IR. The Bloom syndrome protein is
cleaved by caspase 3 in Jurkat cells undergoing apoptosis induced by a
topoisomerase inhibitor (39). Finally, it has been shown that the DNA
repair enzyme Rad51 is cleaved by caspase 3 in cells that have been
exposed to This hypothesis suggests that other DNA repair enzymes are likely to be
degraded in response to treatment with DNA-damaging agents and that
alleles of genes that encode protease-resistant versions of these
proteins could protect cells from death induced by these agents.
The results described herein support this hypothesis. We demonstrate
that DNA ligase III is a substrate for calpain-mediated proteolysis.
Calpain binding to and degradation of DNA ligase III is dependent upon
a PEST (23, 24) sequence that is present in the N-terminal portion of
the latter protein. We further determined that calpain degrades DNA
ligase III during cell death induced by a number of DNA-damaging agents
and that expression of a recombinant DNA ligase III protein that was
resistant to calpain-mediated proteolysis protected cells from killing
by these agents. These findings suggest that calpain-mediated
proteolysis of DNA ligase III plays an essential role in DNA
damage-induced cell death.
Bacterial and Saccharomyces cerevisiae Strains and Eukaryotic
Cells--
Escherichia coli DH10B cells were used for
subcloning of cDNA and for amplification of plasmids recovered from
yeast. For yeast two-hybrid system screening the reporter strains
PJ69-2A (MATa, trp1-901, leu2-3, 112, ura3-52,
his3-200, gal4 Plasmid Constructs--
The two-hybrid vector pAS2-1 containing
the binding domain of Gal4 was purchased from
CLONTECH (Palo Alto, CA). The human cDNA of DNA
ligase III and different fragments of DNA ligase III were cloned
in-frame with the DNA binding domain of Gal4 into pAS2-1. Reverse
transcriptase-PCR was used to amplify nucleotides 73-3102 of the human
DNA ligase III cDNA from HT1080 cells (the nucleotide positions are
based on the DNA ligase III cDNA sequence from
GenBankTM).2 A
second round of PCR was used to create a DNA ligase III minigene encoding a 3'-hemagglutinin (HA) tag (42). This minigene was cloned
into pAS2-1 to create the pAS-FL vector. The pAS-A vector was created
by cloning nucleotides 73-2433 of DNA ligase III into pAS2-1. The
pAS-B vector was created by cloning nucleotides 1411-2293 of DNA
ligase III into pAS2-1. Nucleotides 2433-3102 of DNA ligase III were
cloned into pAS2-1 to create the vector pAS-C. The vector pAS-MOD was
created by subcloning nucleotides 73-2433 of the DNA ligase III
cDNA with the modified PEST sequence into pAS2-1. The full-length
cDNA of wild-type and PEST-modified DNA ligase III were cloned into
the pREP4 vector (Invitrogen) to create the pREP-WT and the pREP-MOD
plasmids, respectively.
Two-hybrid Assay--
A pretransformed Matchmaker human cDNA
liver library cloned into pACT2 (CLONTECH, Palo
Alto, CA) was screened with the pAS-FL as bait. Stable Transfection of Mammalian Cells--
HT1080 cells were
transfected via electroporation (43), and stable transfectants were
isolated based on their antibiotic resistance. Northern blot analyses
were performed on clones that express DNA ligase III RNA.
Cytotoxicity Assays--
Cells were seeded at 1 × 106 cells/100-mm plate. Twenty four hours later, cells were
either pretreated with calpeptin (100 µM; Calbiochem) or
Me2SO (calpeptin vehicle) for 1 h at 37 °C. After preincubation the cells were either exposed to 5 Gy of
Clonogenic Assay--
Hygromycin-resistant HT1080 cells
overexpressing the WT or the PEST-modified DNA ligase III alleles were
used. Hygromycin-resistant HT1080 cells overexpressing the WT DNA
ligase III allele were treated with 100 µM calpeptin for
1 h at 37 °C. The cells were then trypsinized, resuspended at a
concentration of 5 × 105 cells/ml in cold serum-free
media, and exposed to 0, 1.25, or 2.5 Gy of radiation from a
137Cs source. Four hundred cells were then plated on 10-cm
dishes seeded with a feeder layer of hygromycin-sensitive HT1080 cells. Cells were incubated in media containing hygromycin and cultured for 14 days. Colonies were counted by staining with 0.8% crystal violet in
methanol (Sigma), and the ability to survive treatment was
calculated by comparison to unirradiated controls.
Nuclear Extracts--
Nuclear extracts were prepared from HT1080
cells as described previously (42). Protein concentration was measured
using the Bradford assay (44), and bovine serum albumin (BSA; Sigma) was used as standard.
Whole Cell Lysates--
Whole cell lysates were prepared from
HT1080 cells. Cells were collected by scraping and incubated on ice for
10 min in buffer containing 20 mM Tris-HCl, pH 7.8, 500 mM KCl, 0.2% Nonidet P-40, 1 mM
phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 5% glycerol. Lysates were then sonicated on ice (3 bursts
for 15 s) and centrifuged at 10,000 × g for 15 min at 4 °C. The supernatant was collected, and protein
concentration was measured using the Bradford assay.
In Vitro Proteolysis Reactions--
DNA ligase III cDNA was
transcribed and translated during a 90-min incubation at 30 °C in
TNT rabbit reticulocyte lysate (Promega, Madison, WI) using
2 µg of DNA. The TNT reaction mixture (15 µl), 20 µg
of nuclear extract, or 30 µg of whole cell lysate were incubated in
calpain reaction buffer (30 mM Tris-HCl, pH 7.5, and 1.5 mM dithiothreitol) in the presence or absence of 750 µM CaCl2, 1.5 mM EGTA, 1 µg of
purified human calpain, or 520 nM calpeptin (Calbiochem). Samples were brought to a final volume of 40 µl and following incubation at 30 °C for 30 min were placed on ice, and the reaction was terminated by addition of SDS gel-loading buffer (see below). Electrophoresis was performed using a 7.5% polyacrylamide gel. Western
blot analysis was performed as described below.
Western Blot Analysis--
Samples in buffer containing 50 mM Tris-HCl, pH 6.8, 100 mM dithiothreitol, 2%
SDS, 0.1% bromphenol blue, and 10% glycerol, were resolved on
SDS-polyacrylamide gels. Proteins were then transferred onto
nitrocellulose membranes (Bio-Rad) and incubated for several hours in a
solution of Tris-buffered saline (TBS) containing 5% BSA. This
blocking solution was removed, and membranes were incubated overnight
at 4 °C with primary antibody, either a mouse polyclonal anti-DNA
ligase III antibody (Novus Biologicals, Littleton, CO), which
recognizes amino acids 1-862 of DNA ligase III used at a 1:1000
dilution, or a rat monoclonal anti-HA high affinity antibody (clone
3F10; Roche Diagnostics) used at a 1:250 dilution. The membrane was
then washed three times with 0.1% BSA in TBS and incubated for 1 h at room temperature with goat anti-mouse or anti-rat IgG conjugated
with alkaline phosphatase (1:5000 dilution; Sigma). The membrane was
then washed 3 times for 5 min each with TBS and 0.1% BSA. After the
final wash the membrane was incubated with water containing alkaline
phosphatase substrate (SigmaFast, 5-bromo-4-chloro-3-indolyl
phosphate/nitro blue tetrazolium, Sigma). The reaction was stopped by
rinsing the membrane with water, and the blot was scanned and
quantified with the Molecular Analyst program.
Identification of DNA Ligase III PEST Sequence--
The sequence
spanning amino acids 145-158 (KPNNSGEAPSSPTP) of DNA ligase III
was recognized as a PEST sequence by the PEST-FIND algorithm
developed by Rogers and colleagues (45) (www.at.embnet.org/ htbin/embnet/PESTfind).
Site-directed Mutagenesis of DNA Ligase III PEST
Sequence--
Oligonucleotide site-directed mutagenesis of the PEST
sequence of human DNA ligase III was performed using the method of
Kunkel et al. (46). Mutagenic oligonucleotides were used to
alter the coding region corresponding to the PEST domain of DNA ligase
III. The modified cDNA encoded a DNA ligase III protein in which
serine and threonine residues present in the PEST region
(KPNNSGEASSPTP) were replaced by alanines (KPNNAGEAPAAPPAP). In
the process a new SacII restriction site was created. Clones
bearing the desired modifications were identified by restriction digest
using SacII and by DNA sequence analysis. This modified DNA
ligase III cDNA was subcloned into the pAS2-1 vector, creating
plasmid pAS-MOD. Yeast were then co-transformed with this plasmid and
pACT-CAL, the calpain-encoding plasmid identified in the original screen.
Morphological Examination of Irradiated Cells--
HT1080 cells
expressing the WT or PEST-modified DNA ligase III were transiently
transfected (Superfect; Qiagen Inc., Valencia, CA) with a vector
encoding the green fluorescent protein (GFP; CLONTECH, Palo Alto, CA). Following a 48-h
incubation, the cells were exposed to 5 Gy of IR or were
mock-irradiated. One, two, and four hours later fluorescent
photomicroscopy was performed. The samples were coded to eliminate
biased scoring, and 100 cells were examined to determine the relative
percentage of living (flat, adherent) and dying (rounded, shrunken)
cells present before and after irradiation. The results presented in
Fig. 7 were obtained by subtracting the former value from the latter.
DNA Ligase III Interacts with Calpain--
A full-length cDNA
of the human DNA ligase III gene was used as "bait" in a yeast
two-hybrid experiment. Slightly more than 2 million yeast transformants
expressing clones obtained from a human cDNA liver library were
screened to identify potential DNA ligase III-binding proteins. One of
the positive clones harbored a cDNA that upon sequence analysis was
found to encode a portion of the small subunit of the
calcium-dependent protease calpain (amino acids
142-268).3
The N Terminus of DNA Ligase III Interacts with Calpain--
To
determine the calpain-binding region of the DNA ligase III protein,
different fragments of the DNA ligase III cDNA were subcloned into
the two-hybrid vector pAS2-1 thereby creating a series of ligase
III-Gal4 DNA binding domain fusion genes (pAS-FL, pAS-A, pAS-B, and
pAS-C; see "Experimental Procedures"). As Fig. 1A illustrates, the different
cDNA fragments encode one or more of the domains known to be
present in the DNA ligase III protein. Plasmids encoding these fusion
proteins were co-transformed into yeast that expressed the Gal4-calpain
regulatory subunit "prey" fusion protein that was identified in the
original two-hybrid screen (encoded by plasmid pACT-CAL). As Fig.
1B indicates, bait-prey interactions were only detected in
clones that expressed either the full-length DNA ligase III or
construct A, indicating that a calpain-binding domain of DNA ligase III
is located within the N-terminal portion of the protein.
DNA Ligase III Has a PEST Sequence--
Many known calpain
substrates contain a so-called PEST domain (23, 24). PEST domains are
regions of a protein rich in proline, glutamate/aspartate, serine, and
threonine residues that are flanked by basic amino acid residues.
The computer algorithm PEST-Score can be used to determine whether a
particular protein contains a PEST sequence. The algorithm assigns a
score to any PEST sequence identified, and a PEST score greater than 0 suggests that the protein is a likely calpain substrate (45). Computer
analysis revealed the presence of a PEST sequence spanning amino acid
residues 145-158 (single letter amino acid code:
KPNNSGEAPSSPTP, Fig. 1A) of DNA ligase III. The PEST
score for this sequence was +10.47, indicating a strong likelihood that this is an authentic PEST domain. Interestingly, this PEST sequence is
located within the portion of the DNA ligase III protein that interacts
with calpain in the yeast two-hybrid analysis.
Human DNA Ligase III Is a Calpain Substrate--
A series of
experiments were performed to determine whether DNA ligase III is a
substrate for calpain-dependent proteolysis. First, nuclear protein extracts from human HT1080 cells were incubated with calpain under a variety of conditions, resolved by SDS-PAGE, and
DNA ligase III levels monitored by Western blot analysis using an
anti-DNA ligase III antibody. As Fig.
2A indicates, although addition of calpain alone had no effect on DNA ligase III, addition of
calcium (750 µM) plus calpain resulted in complete
degradation of DNA ligase III. As would be expected, when EGTA (a
calcium chelator) was included along with calcium and calpain, no
proteolysis of DNA ligase III was observed. Interestingly, addition of
calcium alone also resulted in partial proteolysis of DNA ligase III, indicating that HT1080 cells possess an endogenous
calcium-dependent protease that is capable of degrading DNA
ligase III.
Similar experiments were performed using nuclear protein extracts
prepared from a HT1080 cell line that overexpressed an HA-tagged DNA
ligase III gene (see "Experimental Procedures"). As Fig.
2B indicates, the HA-tagged DNA ligase III protein present
in extracts prepared from these cells was degraded in the presence of
calcium and calpain. When the specific calpain inhibitor calpeptin was included in the reaction, DNA ligase III was protected from
degradation. As was seen with the endogenous DNA ligase III, addition
of calcium alone resulted in partial degradation of the HA-tagged DNA
ligase III protein.
The results presented in Fig. 2, A and B, are
consistent with the hypothesis that DNA ligase III is a substrate for
calpain proteolysis. However, these results also support the hypothesis that addition of calpain activates a second protease that cleaves DNA
ligase III. To distinguish between these two hypotheses, recombinant DNA ligase III was prepared by in vitro transcription and
translation and was incubated with calpain in the presence or absence
of calcium. As Fig. 2C shows, addition of calpain and 750 µM calcium resulted in DNA ligase III degradation. This
effect was blocked by addition of EGTA or calpeptin. These results
indicate that DNA ligase III is a calpain substrate. This finding in
turn suggests that the degradation of DNA ligase III observed in Fig.
2, A and B, is likely due to the direct action of
calpain. However, these results do not rule out the possibility that
other proteases could be responsible for the
calpain-dependent degradation of DNA ligase III shown in
Fig. 2, A and B.
Characterization of a DNA Ligase III Mutant with a Modified PEST
Sequence--
The results presented thus far are consistent with the
hypothesis that DNA ligase III binds to and is degraded by calpain due
to the presence of a PEST domain near the N terminus of the protein. To
test this hypothesis, site-directed mutagenesis was performed to modify
the portion of the HA-tagged DNA ligase III cDNA that encoded the
PEST sequence. The resulting cDNA encoded a modified DNA ligase III
protein in which three of the serine residues and the threonine residue
within the DNA ligase III PEST domain were replaced by alanine residues
(see the "Experimental Procedures"). Analysis by PEST score
indicated that the DNA ligase III protein encoded by this mutant
cDNA did not possess a recognizable PEST domain.
The modified DNA ligase III cDNA was cloned into an appropriate
vector (pAS-MOD), and a two-hybrid analysis was performed in a yeast
strain that expressed the calpain prey clone isolated from the
original screen. As a control, a parallel experiment was performed with
a yeast clone expressing the wild-type (WT) DNA ligase III cDNA
(pAS-A). Although there was a robust interaction between the calpain
fragment and the WT DNA ligase III, there was no detectable interaction
between calpain and the DNA ligase III protein containing the modified
PEST sequence (data not shown). Western blot analysis revealed that the
respective yeast transformant clones harbored similar levels of the WT
and PEST-modified form of DNA ligase III, suggesting that lack of
interaction between calpain and the PEST-modified DNA ligase III was
not due to instability of the latter protein (data not shown).
Surprisingly, it has not yet been shown directly that PEST sequences
are directly involved in the binding of calpain to any of its substrate
molecules. However, the results described above suggest that binding of
calpain to DNA ligase III is dependent upon a functional PEST sequence,
which is not present on the modified DNA ligase III clone. One clear
prediction of this model is that the modified DNA ligase III protein
should be less sensitive to calpain-mediated degradation than is the WT
DNA ligase III protein. To test this hypothesis, extracts were prepared
from HT1080 cells expressing WT and modified (MOD) DNA ligase III
proteins. These extracts were then incubated in the presence (+) or
absence ( Exposure to 9AC and IR Leads to Calpain-dependent
Degradation of DNA Ligase III and Cell Death--
It is known that
a number of DNA repair enzymes are degraded in cells undergoing
programmed cell death following treatment with topoisomerase
inhibitors (see Introduction). The results presented thus far suggest
that calpain could degrade DNA ligase III in HT1080 cells undergoing
programmed cell death. To test this hypothesis, HT1080 cells were
incubated for 4 h with the topoisomerase I inhibitor 9AC, and the
level of DNA ligase III protein was monitored using Western blot
analysis. As Fig. 4A indicates, there was a time-dependent loss of DNA ligase
III from lysates prepared from 9AC-treated cells. However,
substantially less DNA ligase III degradation was detected in lysates
prepared from 9AC-treated cells that had been preincubated with
calpeptin. As Fig. 4B indicates, pretreatment with calpeptin
significantly reduced the cytotoxic effect of 9AC on HT1080 cells
(p < 0.05, n = 4, ANOVA).
The effect of IR on DNA ligase III levels in HT1080 cells was also
examined. Cell death following exposure to this agent was also
associated with DNA ligase III degradation (Fig. 4C).
Furthermore, cell death was prevented by pretreatment of the cells with
calpeptin (Fig. 4D). It is noteworthy that pretreatment with
calpeptin completely protected cells from death caused by IR, whereas
this compound provided only partial protection against the
cytotoxic effects of 9AC.
We also used a clonogenic assay to examine the ability of calpeptin
pretreatment to confer a long term survival benefit on irradiated
cells. HT1080 cells that expressed an HA-tagged DNA ligase III were
pretreated with calpeptin and then exposed to IR. As Fig. 4E
shows, cells pretreated with calpeptin were completely resistant to
killing by 1.25 or 2.5 Gy of IR. In contrast, cell death was observed
in irradiated cells that had been treated with the calpeptin vehicle
alone. This finding, which is statistically significant
(p < 0.05), confirms that pretreatment with calpeptin protects cells from death induced by IR.
The results presented in Fig. 4 indicate that calpain plays an
essential role in mediating both IR- and 9AC-induced cell death. In
both cases, cell death was associated with degradation of DNA ligase
III. These results are consistent with the hypothesis that DNA ligase
III proteolysis is required for cell death. However, it is equally
plausible that degradation of calpain substrates other than DNA ligase
III is responsible for the cell death caused by these agents.
Creation of HT1080 Cell Lines Expressing WT or PEST-modified
Alleles of DNA Ligase III--
If calpain-dependent
degradation of DNA ligase III were an essential feature of cell death,
cells expressing the calpain-resistant version of this protein should
be less sensitive to the cytotoxic effects of IR and 9AC than cells
expressing WT DNA ligase III. To test this hypothesis, we created
transgenic HT1080 cells that overexpressed the modified or WT DNA
ligase III protein. Before examining the sensitivity of these cell
lines to IR and 9AC, it was essential to characterize them, because
differences in the level of DNA ligase III protein could explain any
differences in their relative sensitivity to DNA-damaging agents.
We first examined whether the two cell lines expressed similar levels
of the two DNA ligase III alleles. As Fig.
5A shows, Western blot
analysis using an antibody that recognizes the HA epitope reveals that
the two cells lines had similar levels of DNA ligase III cross-reacting
protein. Coomassie staining of total proteins showed that this result
was not due to different loading of proteins on the gel (Fig.
5B). However, simply demonstrating that the two cell lines
possess similar levels of DNA ligase III protein is not sufficient,
because it is conceivable that the PEST-modified DNA ligase III protein
possesses greater DNA repair activity than does the WT DNA ligase III
protein. If this were the case, the transgenic clone expressing the
former allele could be inherently less sensitive to killing by
DNA-damaging agents simply due to their enhanced ability to repair the
initial DNA damage. To examine this possibility, the level of DNA
ligase III enzymatic activity present in the transgenic cell lines was
determined. This was accomplished by performing nick-sealing assays on
whole cell extracts prepared from these cell lines. This assay measures the ability of whole cell protein extracts to ligate a substrate that
contains a nicked duplex DNA. The ligase substrate was prepared by
annealing two oligonucleotides (one of which was radioactively labeled)
adjacent to each other on single-stranded M13 phage DNA. This substrate
was incubated with whole cell extracts prepared from HT1080 cells that
overexpressed the WT or modified DNA ligase III, and extracts were
prepared from cells that had been transfected with the empty pREP4
expression vector. A time course of ligation of the two
oligonucleotides was performed, and the formation of the 32-mer product
was determined by electrophoresis on a denaturing polyacrylamide gel
(Fig. 5C). Scanning densitometry was performed on this
image, as well as on images obtained from three additional independent
experiments to quantitate the amount of product formed. This analysis
revealed that, as expected, extracts from both the WT and modified DNA
ligase III-expressing cells had nearly twice as much DNA ligase III
activity as did extracts prepared from control cells (1.8 ± 0.6- and 2.0 ± 0.4-fold, respectively). However, there was no
significant difference between the level of DNA ligase III activity
seen in extracts prepared from either of the two transgenic cell lines
(ANOVA).
A Calpain-resistant Form of DNA Ligase III Protects HT1080 Cells
from Death Induced by IR and 9AC--
By having established that the
cell lines expressing the WT and PEST-modified DNA ligase III alleles
possess similar levels of DNA ligase activity, we examined the relative
sensitivity to these two cell lines to the cytotoxic effects of IR
using a clonogenic assay. These experiments revealed that HT1080 cells
expressing the PEST-modified allele of DNA ligase III protein were
significantly more resistant to killing by IR than were cells that
expressed the WT allele of DNA ligase III (Fig.
6).
An additional series of experiments was performed to evaluate further
the radio-protective effect conferred by the modified version of DNA
ligase III. In these experiments, cells expressing either WT or
modified DNA ligase III were transiently transfected with a vector
encoding the green fluorescent protein (GFP). Following a 48-h
incubation, the cells were irradiated or mock-irradiated. After 1, 2, and 4 h fluorescent photomicrographs were taken. The samples were
coded to permit bias-free scoring, and the relative percentages of
"living" and "dying" cells were determined based upon cell
morphology, with rounded and shrunken cells counted as dying and flat
and adherent cells scored as "alive." This analysis indicated that
greater numbers of cells expressing WT DNA ligase III were dying at 1, 2, and 4 h post-irradiation compared with cells expressing the
PEST-modified form of DNA ligase III (Fig. 7).
Resistance to the Cytotoxic Effects of 9AC and IR in Other Cell
Lines Expressing the PEST-modified DNA Ligase III Allele--
The most
reasonable interpretation of the data presented in Figs. 6 and 7 is
that the protease-resistant form of DNA ligase III protects cells from
killing by IR. However, it is conceivable that other genetic changes
present in this transgenic cell line contribute to the resistance
phenotype. To address this issue, we isolated two additional transgenic
cell lines, one each expressing the WT and PEST-modified alleles of DNA
ligase III. Analysis revealed that the levels of DNA ligase activity
present in nuclear extracts prepared from the two cell lines were not
appreciably different from each other (data not shown). These cell
lines were then tested for their relative sensitivity to the
DNA-damaging agents 9AC and IR. As Table
I reveals, both of the cell lines
expressing the PEST-modified DNA ligase III allele (referred to as
MODA and MODB) are appreciably more resistant
to the cytotoxic effects of these two agents than are the two cell
lines expressing the WT DNA ligase allele (referred to as
WTA and WTB). Interestingly, we observed that
pretreatment with calpeptin provided equal levels of protection from
the cytotoxic effects of these agents to cells, irrespective of whether
they expressed the PEST-modified or WT DNA ligase III alleles (data not
shown).
The results presented herein provide compelling evidence that DNA
ligase III is a physiologically relevant substrate of the calcium-dependent cysteine protease calpain. Calpain binds
to the N-terminal portion of the DNA ligase III protein wherein is located a PEST sequence. A modified form of the DNA ligase III protein
in which the PEST sequence has been modified does not interact with
calpain in the yeast two-hybrid system. In contrast to the WT DNA
ligase III protein, this modified ligase protein is resistant to
in vitro proteolysis by purified calpain. Exposure of human
HT1080 cells to either ionizing radiation or the topoisomerase I
inhibitor camptothecin resulted in DNA ligase III degradation. Pretreatment of these cells with the cell-permeant calpain inhibitor calpeptin simultaneously blocked DNA ligase III degradation and protected the cells from death induced by these agents. We have also
shown that expression of the PEST-modified allele of DNA ligase III
protects cells from IR- and camptothecin-induced cell death.
The finding that protease-resistant versions of both DNA ligase III and
Rad51 (40) protect cells from death induced by IR indicates that their
inactivation is an essential feature of programmed cell death. These
findings indicate that DNA repair enzymes play a fundamental role in
the process of programmed cell death. Because overexpression of
protease-sensitive versions of Rad51 and DNA ligase III provides less
protection than does expression of protease-resistant versions, it is
their ability to resist proteolysis, rather than their DNA repair
activity per se, that is responsible for the protective
effects of the latter enzymes.
Based on these findings, the following model can be proposed. Following
exposure to high levels of IR or other DNA-damaging agents, such as
topoisomerase inhibitors, a cell death signal is propagated. Although
it is tempting to speculate that the trigger for this is the
detection of a threshold level of DNA lesions, this is not a central
feature of the model. One of the consequences of the cell death signal
is the proteolysis of DNA ligase III by calpain. In cells expressing WT
DNA ligase III, proteolysis of this enzyme would result in diminished
cellular DNA repair capacity. As a consequence of the reduced repair
capacity, the DNA lesions created by the ionizing radiation would
persist, causing the cell death signal to continue unabated, ultimately
resulting in cell death. In contrast, these activated proteases fail to degrade the protease-resistant form of DNA ligase III. In these cells, the DNA damage would be repaired, and the cell death signal is
terminated, thus sparing the cells. Here, the critical factor determining whether cells live or die is the length of time that unrepaired DNA lesions persist in the cells. Alternately, one can
propose that nucleases activated in response to DNA damage create
additional genomic damage. This would create an amplification loop that
propagates the cell death signal, leading to cell death. However, cells
expressing a protease-resistant form of DNA ligase III would be able to
repair the induced DNA damage, thereby dampening the amplification
process and enhancing cell survival.
This model suggests that in addition to their structural role in
restoring the integrity of the nuclear genome, DNA repair enzymes such
as Rad51 and DNA ligase III play an important role in fine-tuning the
trigger point of the cell death cascade. This would imply that
relatively small differences in the levels of DNA repair activity that
exist among different cells may have a dramatic effect on the ability
of these cells to survive following exposure to DNA-damaging agents.
This in turn would have a significant implication regarding the
efficacy of cancer chemotherapy regimens in different patients.
-radiation. The degradation of DNA ligase III was prevented by pretreatment with calpeptin, which protected irradiated cells from death. Calpeptin treatment also blocked 9-amino camptothecin-induced DNA ligase III
proteolysis and simultaneously protected the cells from death. HT1080
clones expressing a modified DNA ligase III that lacked a recognizable
PEST domain were significantly more resistant to killing by
-radiation or 9- amino camptothecin than were cells that
overexpressed the wild-type form of DNA ligase III. These data show
that calpain-mediated proteolysis of DNA ligase III plays an essential
role in DNA damage-induced cell death in human cells.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(6), Fas
ligand (7), growth factor withdrawal (8), and DNA-damaging agents (9).
A key feature of apoptosis is the induction of intracellular protease
activity. Biochemical and genetic studies have determined that
proteolytic cleavage of key cellular proteins by these enzymes is an
essential process in the apoptotic pathway (10, 11).
-radiation (40). Interestingly, cells that overexpressed
a protease-resistant form of Rad51 were resistant to the cytotoxic
effects of IR, suggesting that the DNA repair activity mediated by this
enzyme could antagonize the cell death signal, thereby promoting
cellular survival (40).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
, gal80
,
LYS2::GAL1UAS- GAL1TATA-HIS3,
GAL2UAS-GAL2TATA-ADE2) and
Y187 (MAT
, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112, gal4
, gal80
, met
, URA3::
GAL1UAS-GAL1TATA-lacZ)
were used. Human HT1080 fibrosarcoma cells (41) were grown in
Dulbecco's modified Eagle medium (Invitrogen) supplemented with 9%
fetal bovine serum (Invitrogen).
-Galactosidase
filter assays and rescue of plasmids from yeast clones into bacterial
host were performed according to the manufacturer's recommendations.
-radiation (IR) in a 137Cs irradiator or to 10 µM camptothecin (9AC; Calbiochem) in Me2SO. Cell viability was determined by the trypan blue exclusion method after
0, 2, and 4 h.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (30K):
[in a new window]
Fig. 1.
Calpain interacts with human DNA ligase III
in a yeast two-hybrid assay. A, depicted are the
full-length DNA ligase III cDNA and fragments derived from it. A
strong PEST domain (+10.47, PEST-FIND) was identified between amino
acids 145 and 158. B, various DNA ligase III constructs were
co-transformed with the positive clone (pACT-CAL) identified from the
screen. Panel 1, yeast transfected with pAS-FL and pACT-CAL.
Panel 2, yeast transfected with pAS-A and pACT-CAL.
Panel 3, yeast transfected with pAS-B and pACT-CAL.
Panel 4, yeast transfected with pAS-C and pACT-CAL. Growth
on this plate indicates a stable intracellular interaction between the
bait and prey fusion proteins.

View larger version (15K):
[in a new window]
Fig. 2.
DNA ligase III is degraded in
vitro by calpain. A, nuclear extracts (20 µg) from HT1080 were incubated at 30 °C for 30 min with purified
calpain (1 µg) in the presence or absence of calcium (750 µM) or EGTA (1.5 mM). Electrophoresis was
performed using a 7.5% polyacrylamide gel. Western blot analysis was
performed using an antibody that recognizes endogenous DNA ligase III
(LIG3). B, nuclear extracts (20 µg) from HT1080
overexpressing a recombinant HA-DNA ligase III protein were incubated
at 30 °C for 30 min with purified calpain (1 µg) in the presence
or absence of calcium (750 µM) or EGTA (1.5 mM). Calpeptin (520 nM) was used to prevent
calpain activation. Electrophoresis was performed using a 7.5%
polyacrylamide gel. Immunoblot analysis was performed using an antibody
that recognizes the HA epitope. C, 15 µl of in
vitro transcribed and translated DNA ligase III was incubated at
30 °C for 30 min with purified calpain (1 µg) in the presence or
absence of calcium (750 µM) as indicated. EGTA (1.5 mM) and calpeptin (520 nM) were added where
indicated. Electrophoresis was performed using a 7.5% polyacrylamide
gel. Western blot analysis was performed using an antibody that
recognizes the HA epitope.
) of calpain and calcium, and Western blot analysis was
performed using an anti-HA antibody. Fig.
3A depicts a representative
experiment indicating that while the WT DNA ligase III protein was
extremely sensitive to proteolysis by calpain, the modified DNA ligase
III was only partially hydrolyzed. This experiment was repeated several times, and the extent of DNA ligase III degradation was quantitated by
using scanning densitometry. As Fig. 3B indicates, there was a significant difference between the relative sensitivity of the WT and
PEST-modified forms of DNA ligase III to degradation by calpain
(p < 0.001, n = 4, ANOVA).

View larger version (16K):
[in a new window]
Fig. 3.
DNA ligase III protein with a modified PEST
domain is significantly more resistant to degradation by calpain
compared with WT DNA ligase III. A, 30 µg of whole
cell lysates from HT1080 cells that overexpress wild-type (WT) and
PEST-modified (MOD) DNA ligase III (LIG3) were incubated
with (+) or without (
) calcium (750 µM) and purified
calpain (1 µg). Electrophoresis was performed using a 7.5%
polyacrylamide gel. Western blot analysis was performed using an
antibody that recognizes the HA epitope. B, levels of DNA
ligase III were quantified by densitometry. The bar
represents % DNA ligase III immunoreactivity (100% = immunoreactivity
without calpain). Analysis was performed using the Molecular Analyst
software. Results represent mean ± S.E. of three independent
experiments. *, p < 0.05 compared with PEST modified
DNA ligase III (MOD). Black bars, plus calpain
and calcium; white bars, minus calpain and calcium.

View larger version (24K):
[in a new window]
Fig. 4.
Calpain-dependent DNA ligase III
degradation and cell death in response to 9AC and IR treatment.
A, HT1080 cells expressing an HA-tagged allele of WT DNA
ligase III were pretreated with calpeptin (100 µM; +) or
Me2SO (
) for 1 h at 37 °C. Cells were then
exposed to 10 µM 9AC, and whole cell lysates were
prepared at 0 and 4 h after treatment. Electrophoresis was
performed using a 7.5% polyacrylamide gel. Western blot analysis was
performed by using an antibody that recognizes the HA epitope.
B, HT1080 cells expressing the HA-tagged WT DNA ligase III
were pretreated with 100 µM calpeptin (black
bars) or calpeptin-vehicle (white bars) for 1 h at
37 °C. Cells were then exposed to 9AC (10 µM) for 2 and 4 h. Cells survival was measured as described under
"Experimental Procedures." Results represent the mean ± S.E.
of four independent experiments. *, p < 0.05 (ANOVA)
compared with untreated cells before 9AC exposure. C, HT1080
cells expressing the HA-tagged WT DNA ligase III were pretreated with
calpeptin (100 µM; +) or Me2SO (
) for
1 h at 37 °C. Cells were then exposed to 5 Gy of IR, and whole
cell lysates were prepared at 0 and 4 h after treatment.
Electrophoresis was performed using a 7.5% polyacrylamide gel. Western
blot analysis was performed by using an antibody that recognizes the HA
epitope. D, HT1080 cells expressing the HA-tagged WT DNA
ligase III were pretreated with 100 µM calpeptin
(black bars) or calpeptin vehicle (white bars)
for 1 h at 37 °C. Then the cells were exposed to 5 Gy of IR. At
0, 2, and 4 h post-irradiation, cells were collected and counted,
and percent survival was calculated. Results represent the mean ± S.E. of four independent experiments. *, p < 0.05 (ANOVA) compared with unirradiated cells. E, HT1080
cells expressing the HA-tagged WT DNA ligase III were pretreated with
100 µM calpeptin (black bars) or calpeptin
vehicle (white bars) for 1 h at 37 °C. The cells
were then exposed to 0, 1.25, or 2.5 Gy of radiation. Cells were grown
in hygromycin media, and after 14 days colonies were stained with
crystal violet. Colonies were counted, and percent survival was
calculated compared with unirradiated cells. Results represent the
mean ± S.E. of three independent experiments. *,
p < 0.05 (ANOVA) compared with unirradiated
cells.

View larger version (42K):
[in a new window]
Fig. 5.
WT and PEST-modified alleles of DNA ligase
III have similar levels of proteins and of nick-sealing activity.
A, nuclear extracts from HT1080 cells that express the
HA-tagged wild-type (WT), HA-tagged PEST modified
(MOD) DNA ligase III, or the empty vector (C)
were electrophoresed on a 7.5% polyacrylamide gel. Immunoblot analysis
was performed using an antibody that recognizes the HA epitope.
B, nuclear extracts from HT1080 cells that overexpress
wild-type (WT), PEST-modified (MOD) DNA ligase
III, or the empty vector (C) were electrophoresed on a 10%
polyacrylamide gel and stained with Coomassie Brilliant Blue.
C, whole cell lysates were prepared from HT1080 cells
overexpressing the wild-type (WT), or the PEST-modified DNA
ligase III (MOD), or the empty vector (pREP4) and
their ability to seal a nick in a DNA-DNA duplex substrate was assayed.
Reactions were carried out as described under "Experimental
Procedures," with extracts incubated at the indicated times (min).
The lower band represents unligated substrate DNA. The
upper band (arrow) represents the ligated DNA
products.

View larger version (16K):
[in a new window]
Fig. 6.
The PEST-modified allele of DNA ligase III
protects cells from death. HT1080 cells overexpressing the
wild-type (squares) or the PEST-modified allele of DNA
ligase III (diamonds) were exposed to 0, 1.25, or 2.5 Gy of
radiation. Colonies were counted, and the percent survival was
calculated compared with unirradiated controls. Results represent the
mean ± S.E. of three independent experiments. *,
p < 0.05 (ANOVA) compared with unirradiated
cells.

View larger version (20K):
[in a new window]
Fig. 7.
Overexpression of the PEST-modified form of
DNA ligase III prevents IR-mediated cell death. HT1080 cells
overexpressing the wild-type (squares) or the PEST-modified
allele of DNA ligase III (diamonds) were transiently
transfected with a vector that encoded the GFP protein. After 48 h
cells were exposed to 5 Gy of radiation. Cell morphology was scored 1, 2, and 4 h after IR (see "Experimental Procedures"). Values
represent the mean of two independent experiments. *, p < 0.05 (ANOVA) compared with wild-type.
Cell lines expressing the PEST-modified DNA ligase III allele
(MODA and MODB) are more resistant to the cytotoxic
effects of IR and 9AC than cells expressing the WT DNA ligase allele
(WTA and WTB)
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENT |
|---|
Uma Lakshmipathy provided excellent editorial advice.
| |
FOOTNOTES |
|---|
* This work was supported in part by National Institutes of Health Grants CA61906 and AG16678 and the American Heart Association.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Supported by American Heart Association Northland Affiliate
Predoctoral Fellowship 9951198Z.
§ To whom correspondence should be addressed: Dept. of Pharmacology, University of Minnesota Medical School, 6-120 Jackson Hall, 321 Church St., SE, Minneapolis, MN 55455. Tel.: 612-625-8986; Fax: 612-625-8408; E-mail: campb034@umn.edu.
Published, JBC Papers in Press, May 6, 2002, DOI 10.1074/jbc.M112037200
2 The nucleotide sequence for the human DNA ligase III was deposited in GenBankTM under accession number AAA85022.
3 The amino acid sequence for the human calpain small subunit can be accessed through NCBI Protein Database under accession number P04632.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: PEST, proline, aspartate, serine, and threonine; 9AC, 9-amino camptothecin; IR, ionizing radiation; WT, wild-type; HA, hemagglutinin; PARP, poly(ADP-ribose) polymerase; FL, full length; GFP, green fluorescent protein; BSA, bovine serum albumin; TBS, Tris-buffered saline; Gy, gray; ANOVA, analysis of variance; MOD, modified.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Arends, M. J., and Wyllie, A. H. (1991) Int. Rev. Exp. Pathol. 32, 223-254[Medline] [Order article via Infotrieve] |
| 2. | Ellis, R. E., Yuan, J. Y., and Horvitz, H. R. (1991) Annu. Rev. Cell Biol. 7, 663-698[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Cohen, J. J., Duke, R. C., Fadok, V. A., and Sellins, K. S. (1992) Annu. Rev. Immunol. 10, 267-293[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Vaux, D. L., Haecker, G., and Strasser, A. (1994) Cell 76, 777-779[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Debbas, M.,
and White, E.
(1993)
Genes Dev.
7,
546-554 |
| 6. |
Kim, M. Y.,
Linardic, C.,
Obeid, L.,
and Hannun, Y.
(1991)
J. Biol. Chem.
266,
484-489 |
| 7. |
Trauth, B. C.,
Klas, C.,
Peters, A. M.,
Matzku, S.,
Moller, P.,
Falk, W.,
Debatin, K. M.,
and Krammer, P. H.
(1989)
Science
245,
301-305 |
| 8. | Kulkarni, G. V., and McCulloch, C. A. (1994) J. Cell Sci. 107, 1169-1179[Abstract] |
| 9. | Li, L., Story, M., and Legerski, R. J. (2001) Int. J. Radiat. Oncol. Biol. Phys. 49, 1157-1162[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Stroh, C., and Schulze-Osthoff, K. (1998) Cell Death Differ. 5, 997-1000[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Earnshaw, W. C., Martins, L. M., and Kaufmann, S. H. (1999) Annu. Rev. Biochem. 68, 383-424[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Xue, D.,
Shaham, S.,
and Horvitz, H. R.
(1996)
Genes Dev.
10,
1073-1083 |
| 13. | Deiss, L. P., Galinka, H., Berissi, H., Cohen, O., and Kimchi, A. (1996) EMBO J. 15, 3861-3870[Medline] [Order article via Infotrieve] |
| 14. |
Sarin, A.,
Adams, D. H.,
and Henkart, P. A.
(1993)
J. Exp. Med.
178,
1693-1700 |
| 15. | Roberts-Lewis, J. M., Marcy, V. R., Zhao, Y., Vaught, J. L., Siman, R., and Lewis, M. E. (1993) J. Neurochem. 61, 378-381[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Squier, M. K., and Cohen, J. J. (1997) J. Immunol. 158, 3690-3697[Abstract] |
| 17. | Erickson, A. H. (1989) J. Cell. Biochem. 40, 31-41[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Suzuki, K.,
Tsuji, S.,
Ishiura, S.,
Kimura, Y.,
Kubota, S.,
and Imahori, K.
(1981)
J. Biochem. (Tokyo)
90,
1787-1793 |
| 19. |
DeMartino, G. N.,
Huff, C. A.,
and Croall, D. E.
(1986)
J. Biol. Chem.
261,
12047-12052 |
| 20. |
Inomata, M.,
Kasai, Y.,
Nakamura, M.,
and Kawashima, S.
(1988)
J. Biol. Chem.
263,
19783-19787 |
| 21. |
Elce, J. S.,
Hegadorn, C.,
and Arthur, J. S.
(1997)
J. Biol. Chem.
272,
11268-11275 |
| 22. | Budihardjo, I., Oliver, H., Lutter, M., Luo, X., and Wang, X. (1999) Annu. Rev. Cell Dev. Biol. 15, 269-290[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Carafoli, E., and Molinari, M. (1998) Biochem. Biophys. Res. Commun. 247, 193-203[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Wang, K. K., Villalobo, A., and Roufogalis, B. D. (1989) Biochem. J. 262, 693-706[Medline] [Order article via Infotrieve] |
| 25. | Cardone, M. H., Salvesen, G. S., Widmann, C., Johnson, G., and Frisch, S. M. (1997) Cell 90, 315-323[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. (1998) Nature 391, 43-50[CrossRef][Medline] [Order article via Infotrieve] |
| 27. |
Kothakota, S.,
Azuma, T.,
Reinhard, C.,
Klippel, A.,
Tang, J.,
Chu, K.,
McGarry, T. J.,
Kirschner, M. W.,
Koths, K.,
Kwiatkowski, D. J.,
and Williams, L. T.
(1997)
Science
278,
294-298 |
| 28. |
Wood, D. E.,
and Newcomb, E. W.
(1999)
J. Biol. Chem.
274,
8309-8315 |
| 29. |
Gervais, J. L.,
Seth, P.,
and Zhang, H.
(1998)
J. Biol. Chem.
273,
19207-19212 |
| 30. |
Kayalar, C.,
Ord, T.,
Testa, M. P.,
Zhong, L. T.,
and Bredesen, D. E.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
2234-2238 |
| 31. | Mashima, T., Naito, M., Fujita, N., Noguchi, K., and Tsuruo, T. (1995) Biochem. Biophys. Res. Commun. 217, 1185-1192[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Mashima, T., Naito, M., and Tsuruo, T. (1999) Oncogene 18, 2423-2430[CrossRef][Medline] [Order article via Infotrieve] |
| 33. |
Shao, R. G.,
Cao, C. X.,
and Pommier, Y.
(1997)
J. Biol. Chem.
272,
31321-31325 |
| 34. | Voelkel-Johnson, C., Entingh, A. J., Wold, W. S., Gooding, L. R., and Laster, S. M. (1995) J. Immunol. 154, 1707-1716[Abstract] |
| 35. |
Widmann, C.,
Gibson, S.,
and Johnson, G. L.
(1998)
J. Biol. Chem.
273,
7141-7147 |
| 36. | Song, Q., Lees-Miller, S. P., Kumar, S., Zhang, Z., Chan, D. W., Smith, G. C., Jackson, S. P., Alnemri, E. S., Litwack, G., Khanna, K. K., and Lavin, M. F. (1996) EMBO J. 15, 3238-3246[Medline] [Order article via Infotrieve] |
| 37. | McGinnis, K. M., Gnegy, M. E., Park, Y. H., Mukerjee, N., and Wang, K. K. (1999) Biochem. Biophys. Res. Commun. 263, 94-99[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Tong, X., Liu, B., Dong, Y., and Sun, Z. (2000) Int. J. Radiat. Biol. 76, 1387-1395[CrossRef][Medline] [Order article via Infotrieve] |
| 39. |
Freire, R.,
d'Adda Fagagna, F., Wu, L.,
Pedrazzi, G.,
Stagljar, I.,
Hickson, I. D.,
and Jackson, S. P.
(2001)
Nucleic Acids Res.
29,
3172-3180 |
| 40. |
Huang, Y.,
Nakada, S.,
Ishiko, T.,
Utsugisawa, T.,
Datta, R.,
Kharbanda, S.,
Yoshida, K.,
Talanian, R. V.,
Weichselbaum, R.,
Kufe, D.,
and Yuan, Z. M.
(1999)
Mol. Cell. Biol.
19,
2986-2997 |
| 41. | Rasheed, S., Nelson-Rees, W. A., Toth, E. M., Arnstein, P., and Gardner, M. B. (1974) Cancer (Phila.) 33, 1027-1033 |
| 42. |
Lakshmipathy, U.,
and Campbell, C.
(1999)
Mol. Cell. Biol.
19,
3869-3876 |
| 43. | Keown, W. A., Campbell, C. R., and Kucherlapati, R. S. (1990) Methods Enzymol. 185, 527-537[Medline] [Order article via Infotrieve] |
| 44. | Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve] |
| 45. |
Rogers, S.,
Wells, R.,
and Rechsteiner, M.
(1986)
Science
234,
364-368 |
| 46. | Kunkel, T. A., Roberts, J. D., and Zakour, R. A. (1987) Methods Enzymol. 154, 367-382[Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
S. Hata, N. Doi, F. Kitamura, and H. Sorimachi Stomach-specific Calpain, nCL-2/Calpain 8, Is Active without Calpain Regulatory Subunit and Oligomerizes through C2-like Domains J. Biol. Chem., September 21, 2007; 282(38): 27847 - 27856. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Radivojac, L. M. Iakoucheva, C. J. Oldfield, Z. Obradovic, V. N. Uversky, and A. K. Dunker Intrinsic Disorder and Functional Proteomics Biophys. J., March 1, 2007; 92(5): 1439 - 1456. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hata, S. Koyama, H. Kawahara, N. Doi, T. Maeda, N. Toyama-Sorimachi, K. Abe, K. Suzuki, and H. Sorimachi Stomach-specific Calpain, nCL-2, Localizes in Mucus Cells and Proteolyzes the beta-Subunit of Coatomer Complex, beta-COP J. Biol. Chem., April 21, 2006; 281(16): 11214 - 11224. [Abstract] [Full Text] [PDF] |
||||
![]() |
|